论文部分内容阅读
目的:探讨皮肤恶性黑素瘤中miR-34c的表达以及相应的临床意义。方法:收集47例皮肤恶性黑素瘤患者组织标本,采用RNA核酸印迹法检测miR-34c的表达,同时检测31例来源于整形外科的正常皮肤组织标本作对照,分析miR-34c与临床分期、肿瘤大小、病灶数目及淋巴结转移等临床病理特征的关系。结果:miR-34c在皮肤恶性黑素瘤组织中的表达显著低于正常对照组(P<0.05);miR-34c低表达与临床分期(P<0.05)、病灶数目(P<0.05)及淋巴结转移有关(P<0.05),而与患者的年龄、性别、肿瘤大小无明显相关性(P>0.05)。结论:miR-34c可能以抑癌基因的方式参与恶性黑素瘤的发生与发展,检测miR-34c的表达水平可能会为恶性黑素瘤的个性化治疗提供新的思路。miR-34c有可能成为靶向药物作用的靶点。
Objective: To investigate the expression of miR-34c in cutaneous malignant melanoma and its clinical significance. Methods: Tissue samples from 47 patients with malignant melanoma were collected. The expression of miR-34c was detected by RNAi. Meanwhile, 31 normal skin specimens from orthopedics were collected as controls. The relationship between miR-34c and clinical stage, Tumor size, the number of lesions and lymph node metastasis and other clinicopathological features. Results: The expression of miR-34c in malignant melanoma tissue was significantly lower than that in the normal control group (P <0.05). The expression of miR-34c was significantly lower than the clinical stage (P <0.05) (P <0.05), but not with age, sex and tumor size (P> 0.05). Conclusion: miR-34c may be involved in the occurrence and development of malignant melanoma by means of tumor suppressor gene. Detecting the expression level of miR-34c may provide a new idea for the personalized treatment of malignant melanoma. miR-34c may be the target of targeted drug effects.